- About Us
- Nano-Social Network
- Nano Consulting
- My Account
Lux Research report reveals that many of the world’s largest corporations are failing to invest wisely in nanotechnology
Global corporations are investing heavily in nanotechnology development—increasing their commitment in money, people and partnerships. But most fail to tie these activities to an explicit strategy or coordinate their efforts across the company – leaving their investments at risk of being wasted, according to a new report from Lux Research entitled “The CEO’s Nanotechnology Playbook.”
“Companies that pursue uncoordinated nanotech efforts may be caught blindsided by better-organized competitors and fleet-footed startups,” said Lux Research Vice President of Research Matthew Nordan. “Toshiba could see its $1.8 billion in annual flash memory sales displaced by nano-enabled alternatives, and nano-fabric treatments could erode the 29% of revenue that P&G earns from fabric and home care products.”
To uncover how companies organize their nanotechnology initiatives today, Lux Research conducted in-depth, confidential interviews with executives accountable for nanotechnology at 33 global corporations with more than $5 billion in annual revenue. The median company represented recorded sales of $30 billion last year and employs 46,000 people. Interviewees were balanced across three sectors impacted by nanotechnology – manufacturing and materials, electronics and IT, and healthcare and life sciences – as well as across North America, Asia, and Europe.
“Large companies have not converged on any particular model for organizing and governing their nanotechnology initiatives,” said Nordan. “The diverse approaches that we found show no correlation with industry, region, company size, years of experience in working at the nanoscale, or the presence or absence of an explicit nanotechnology strategy. Most companies’ efforts reflect awkwardness in grappling with technology innovations that don’t mesh well with their existing organizations rather than carefully crafted initiatives.”
Highlights of the report’s interview data include:
Lux Research advises that nanotechnology is too diverse for companies to take any single approach to exploiting it. Instead, large firms should regularly screen the universe of relevant opportunities arising from nanotechnology and match each with an appropriate organization and set of management tactics.
“The key is to segment nanotechnology opportunities on two axes,” said Nordan. “First, does the opportunity represent a process innovation that stops at the factory door or a product innovation that is visible to customers? Second, does the opportunity present an evolutionary advance that matches existing competencies or a revolutionary advance that requires new ones? The answers to these questions determine which mix of organizational approaches a company should pursue in developing nanotechnology.”
The report provides a decision tool for segmenting nanotechnology opportunities and presents case studies of two global corporations. It is available immediately to clients of Lux Research’s Nanotechnology Strategies advisory service. For information on how to become a client, contact Rob Burns, Vice President of Sales, at (646) 723-0708.
About Lux Research:
Lux Research is the world's premier research and advisory firm focusing on the business and economic impact of nanotechnology and related emerging technologies. Lux Research provides continuous advisory services, customized consulting, and reference studies to corporations, start-ups, financial institutions, and public sector organizations. Our founders and our research staff are the most widely recognized nanotechnology visionaries throughout the world. Visit www.luxresearchinc.com for more information.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Arrowhead Provides Response to New Minority Shareholder Announcement January 7th, 2017
Harris & Harris Group Announces a Proposed Strategic Restructuring December 20th, 2016
NovAliX Turns to High-Resolution Cryo-Transmission Electron Microscopy for Pre-Clinical Drug Discovery Research: Thermo Fisher Scientific’s Cryo-TEM provides critical information for small molecule and biologic drug discovery February 28th, 2017
Dream Chip Technologies Presents First 22nm FD-SOI Silicon of New Automotive Driver Assistance SoC: Advanced driver assistance system (ADAS) computer vision SoC developed for European THINGS2DO project with working first silicon fabricated on GLOBALFOUNDRIES’ 22nm FD-SOI Platfor February 27th, 2017